Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss
Share
Why It Matters
Structure Therapeutics tested a new weight-loss medicine and saw people lose up to 16% of their weight over time without stopping improvement. When a medicine shows it keeps working and doesn't plateau (flatten out), that's a sign the company's research is moving in a promising direction.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.